Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. therapnea

Therapnea SIGNED

Therapnea: Novel Therapy to treat Obstructive Sleep Apnea based on Thomas Oro-Pharyngeal Stent

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 Therapnea project word cloud

Explore the words cloud of the Therapnea project. It provides you a very rough idea of what is the project "Therapnea" about.

first    compressed    tens    morbidity    positive    successful    ltd    mortality    walls    continuous    million    therapnea    millions    suffer    cagr    50    intended    2023    pharynx    discomfort    stop    respiratory    obstructive    causing    mainly    airway    thereby    treatment    market    disruptive    co    surgery    worth    billion    therapies    pressure    ways    companies    partial    8    unable    regarding    occluded    apnea    cpap    keep    worldwide    patients    organisation    health    organic    behavioural    world    becomes    invention    back    medical    limitations    severe    issue    none    preventing    tongue    size    usd    line    people    unfortunately    patient    sleep    solution    trade    7    adhere    compliance    surgeries    complete    operates    upper    air    therapy    2016    breathing    eliminating    thomas    abandon    disorder    stenting    mechanical    helped    unmet    device    airways    obstruction    usually    adult    risks    collapse   

Project "Therapnea" data sheet

The following table provides information about the project.

Coordinator		 THOMAS MEDICAL LTD 

Organization address
address: 6 ALONEI NISSIM
city: TEL AVIV
postcode: 6291920
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Israel [IL]
 Project website http://www.therapnea.net
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2018-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THOMAS MEDICAL LTD IL (TEL AVIV) coordinator 50˙000.00

Map

 Project objective

Obstructive sleep apnea is the most common organic sleep disorder in which the respiratory path becomes occluded during sleep, usually due to collapse of the upper airways, causing the patient to stop breathing, with severe co-morbidity issues. Although there are several known therapies for apnea (behavioural, devices or surgery), none is as successful and effective as using compressed air respiratory support to keep the airways open during sleep, making CPAP (Continuous Positive Airway Pressure) the most common treatment of choice. Unfortunately, it still has many limitations regarding patient’s compliance, and it is ONLY SUCCESSFUL FOR 50% OF PATIENTS. According to the World Health Organisation (WHO), over 100 Million people worldwide suffer sleep apnea and its related morbidity and mortality risks. Tens of millions are unable to adhere or abandon current therapies, with CPAP as the first line of treatment. Low CPAP compliance, mainly due to major discomfort, is recognized as the major issue, and many companies are investigating ways to improve it. Sleep apnea devices market size is worth USD 8.8 billion by 2023, with 7.7% CAGR from 2016 to 2023. We at Thomas Medical Ltd. have been working on the development of a disruptive solution to respond to the unmet needs of patients that can’t adhere current therapies. The invention is an upper airway stenting device intended for the treatment of adult obstructive sleep apnea. The device, Therapnea™, operates by providing mechanical support to the walls of the pharynx and the back of the tongue, thereby preventing their collapse and eliminating partial or complete airway obstruction during sleep. We aim to provide effective therapy to the tens of millions of sleep apnea patients who can’t be helped with current CPAP devices or surgeries, and thus become the first line of treatment in the long term.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERAPNEA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERAPNEA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More